Literature DB >> 34674084

A retrospective study of nine patients with progressive pseudorheumatoid dysplasia: to explore early diagnosis and further treatment.

Lei Yin1,2, Youying Mao3, Yunfang Zhou4, Yongnian Shen4, Huijin Chen4, Wei Zhou3, Yanliang Jin5, Hua Huang5, Yongguo Yu6, Jian Wang7.   

Abstract

OBJECTIVES: Most patients with progressive pseudorheumatoid dysplasia (PPRD) are initially misdiagnosed because of disease rarity and lack of awareness by most clinicians. The purpose of this study was to provide further early diagnostic options and potential treatment to patients with PPRD.
METHODS: A retrospective study was performed by collecting and organizing clinical manifestations, radiographic features, laboratory test results, genetic test outcome, treatment, and follow-up records of the patients with PPRD. Age of diagnosis and genotype-phenotype correlation were further analyzed.
RESULTS: Nine PPRD children with causative CCN6 mutation were included. There were 3 pairs of siblings and 1 patient from inbred family. Five patients were primarily misdiagnosed as juvenile idiopathic arthritis (JIA). The interval between onset of symptoms and definite diagnosis of 8 patients varied from 3.6 to 20 years. Symptoms at the onset included enlarged and stiff interphalangeal joints of the fingers, gait disturbance, or joint pain. Laboratory tests revealed normal range of inflammatory parameters. Radiographic findings disclosed different degrees of abnormal vertebral bodies and epiphyseal enlargement of the interphalangeal joints. After the treatment of calcitriol in 5 patients with low level 25-hydroxyvitamin D3 for around 1.25 years to 1.75 years, 2 patients kept stable, while 3 of them improved gradually.
CONCLUSIONS: Combining the patient's family history, clinical features, normal inflammatory markers, and the characteristic radiographic findings, the clinical diagnosis of PPRD for the patients could be obtained at very early stage of the disease. The patients with PPRD carrying c.624dupA variant in CCN6 may have delayed onset. Underlying vitamin D deficiency should be sought and corrected in patients with PPRD.
© 2021. International League of Associations for Rheumatology (ILAR).

Entities:  

Keywords:  Articular cartilage; CCN6 gene variant; Noninflammatory; Progressive pseudorheumatoid dysplasia; Vitamin D deficiency

Mesh:

Year:  2021        PMID: 34674084     DOI: 10.1007/s10067-021-05959-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  1,25(OH)2D3 promotes chondrocyte apoptosis and restores physical function in rheumatoid arthritis through the NF-κB signal pathway.

Authors:  Run Tian; Xiaofang Li; Yue Li; Kunzheng Wang; Chunsheng Wang; Pei Yang
Journal:  Biomed Pharmacother       Date:  2018-06-27       Impact factor: 6.529

Review 2.  Progressive pseudorheumatoid dysplasia: a rare childhood disease.

Authors:  Sofia Torreggiani; Marta Torcoletti; Belinda Campos-Xavier; Francesco Baldo; Carlo Agostoni; Andrea Superti-Furga; Giovanni Filocamo
Journal:  Rheumatol Int       Date:  2018-10-16       Impact factor: 2.631

3.  Effects of 1,25-Dihydroxy vitamin D3 on TNF-α induced inflammation in human chondrocytes and SW1353 cells: a possible role for toll-like receptors.

Authors:  Gamze Avcioglu; Betül Özbek Ipteç; Gülben Akcan; Büsra Görgün; Kübra Fidan; Ahmet Carhan; Gulsen Yilmaz; Leyla Didem Kozaci
Journal:  Mol Cell Biochem       Date:  2019-11-16       Impact factor: 3.396

4.  Patients with progressive pseudorheumatoid dysplasia: from clinical diagnosis to molecular studies.

Authors:  Jun Ye; Hui-Wen Zhang; Wen-Juan Qiu; Lian-Shu Han; Ya-Fen Zhang; Zhu-Wen Gong; Xue-Fan Gu
Journal:  Mol Med Rep       Date:  2011-10-11       Impact factor: 2.952

5.  Cellular and molecular responses in progressive pseudorheumatoid dysplasia articular cartilage associated with compound heterozygous WISP3 gene mutation.

Authors:  Hou-De Zhou; Yan-Hong Bu; Yi-Qun Peng; Hui Xie; Min Wang; Lin-Qing Yuan; Yi Jiang; Duo Li; Qi-You Wei; Yu-Ling He; Tao Xiao; Jiang-Dong Ni; Er-Yuan Liao
Journal:  J Mol Med (Berl)       Date:  2007-05-05       Impact factor: 4.599

6.  Progressive pseudorheumotoid dysplasia: A presentation of four cases with slow and rapid progression and effects of early rehabilitation program.

Authors:  Esra Giray; İlker Yağcı; Huriye Nursel Elçioğlu
Journal:  Turk J Phys Med Rehabil       Date:  2019-01-29

7.  A homozygous deletion of exon 1 in WISP3 causes progressive pseudorheumatoid dysplasia in two siblings.

Authors:  Barbara Neerinckx; Cedric Thues; Carine Wouters; Sarah Lechner; Rene Westhovens; Hilde Van Esch
Journal:  Hum Genome Var       Date:  2015-12-03

8.  Progressive Pseudorheumatoid Dysplasia resolved by whole exome sequencing: a novel mutation in WISP3 and review of the literature.

Authors:  Ben Pode-Shakked; Asaf Vivante; Ortal Barel; Shai Padeh; Dina Marek-Yagel; Alvit Veber; Shachar Abudi; Aviva Eliyahu; Irit Tirosh; Shiri Shpilman; Shirlee Shril; Friedhelm Hildebrandt; Mordechai Shohat; Yair Anikster
Journal:  BMC Med Genet       Date:  2019-03-29       Impact factor: 2.103

9.  Progressive pseudorheumatoid dysplasia with new-found gene mutation of Wntl inducible signaling pathway protein 3.

Authors:  Wenji Chen; Shiyan Mo; Gui Luo; Yanyan Wang; Xiaohu Deng; Jian Zhu; Wei Zhao
Journal:  Pediatr Rheumatol Online J       Date:  2018-09-10       Impact factor: 3.054

10.  Coexistence of a novel WISP3 pathogenic variant and an MEFV mutation in an Arabic family with progressive pseudorheumatoid dysplasia mimicking polyarticular juvenile idiopathic arthritis.

Authors:  Basil M Fathalla; Elham Ahmed Elgabaly; Ahmad Abou Tayoun
Journal:  Pediatr Rheumatol Online J       Date:  2020-09-07       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.